Valuation: Alvotech

Market Cap 1.1B 966M 900M 826M 1.55B 105B 1.57B 10.69B 4.18B 52.06B 4.13B 4.04B 180B P/E 2026 *
8.36x
P/E 2027 * 7.13x
Enterprise Value 2.15B 1.89B 1.76B 1.61B 3.03B 206B 3.07B 20.89B 8.16B 102B 8.06B 7.89B 351B EV / Sales 2026 *
3.25x
EV / Sales 2027 * 2.73x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day+0.65%
1 week-9.68%
Current month-16.53%
1 month-16.30%
3 months-6.67%
6 months-42.00%
Current year-39.96%
1 week 3.04
Extreme 3.04
3.52
1 month 3.04
Extreme 3.04
3.95
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.94
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 28/02/2026
Director of Finance/CFO 48 09/07/2025
Chief Tech/Sci/R&D Officer - 31/12/2022
Director TitleAgeSince
Chairman 56 31/12/2018
Director/Board Member 64 31/12/2018
Director/Board Member 58 31/12/2018
Date Insider Type Main position Quantity % Market Cap.
01/04/26 Free

Chief Executive Officer

117,271 0.0355%
01/04/26 Buy

Founder

318,000 0.0963%
01/04/26 Sell

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%-9.68%-67.95%-67.98% 1.1B
+0.04%-0.74%-0.96%+10.94% 47.74B
-0.61%+4.26%+396.16%+647.20% 39.98B
0.00%+4.93%+11.81%+55.56% 36.23B
+2.48%+4.57%+7.05%-5.05% 35.59B
+0.62%+3.53%+5.41%+42.19% 27.91B
-0.17%+0.66% - - 16.71B
-2.00%+11.64%+31.71%+136.81% 16.45B
-0.03%-3.96%+2.26%+7.35% 13.21B
+1.82%+1.56%-9.75%-30.15% 12.93B
Average +0.95%+1.24%+41.75%+88.54% 24.79B
Weighted average by Cap. +1.25%+2.87%+73.44%+135.38%

Financials

2026 *2027 *
Net sales 661M 581M 541M 497M 933M 63.37B 945M 6.43B 2.51B 31.29B 2.48B 2.43B 108B 800M 703M 654M 601M 1.13B 76.7B 1.14B 7.78B 3.04B 37.87B 3B 2.94B 131B
Net income 165M 145M 135M 124M 232M 15.78B 235M 1.6B 625M 7.79B 618M 605M 26.94B 134M 118M 110M 101M 190M 12.89B 192M 1.31B 510M 6.36B 504M 494M 21.99B
Net Debt 1.05B 921M 858M 788M 1.48B 101B 1.5B 10.2B 3.98B 49.64B 3.93B 3.85B 172B 1.08B 950M 884M 812M 1.53B 104B 1.55B 10.51B 4.11B 51.18B 4.06B 3.97B 177B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
27/07/26 US$3.080 +0.65% 397,899
24/07/26 US$3.060 -3.77% 588,655
23/07/26 US$3.180 -0.31% 1,179,396
22/07/26 US$3.190 -9.38% 1,476,739
21/07/26 US$3.520 +3.23% 440,710
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.080USD
Average target price
6.500USD
Spread / Average Target
+111.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock